Crinetics Pharmaceuticals, a San Diego biotech focused on developing new drugs for endocrine disorders and endocrine-related cancers, said today it has raised $63.5 million in a Series B financing led by Perceptive Advisors, the New York biotech fund.
Two new investors, RA Capital and OrbiMed, joined the round, along with existing investors 5AM Ventures, Versant Ventures, and Vivo Capital. With the latest funding, CEO Scott Struthers, who founded Crinetics in 2008, said the company has raised over $100 million, including private investments and non-dilutive funding such as Small Business Innovation Research Grants.
In a statement Tuesday, Crinetics said it plans… Read more »
UNDERWRITERS AND PARTNERS